Research Article

The Level and Significance of Circulating Angiotensin-III in Patients with Coronary Atherosclerosis

Guoqing Yao,1 Wenjing Li,2 Wenzhao Liu,1 Jingbo Xing,1 and Cheng Zhang1

1The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Qilu Hospital, Cheleq College of Medicine, Shandong University, Jinan, Shandong 250012, China
2Fine Arts School of Shandong University, Jinan, Shandong 250012, China

Correspondence should be addressed to Cheng Zhang; zhangc@sdu.edu.cn

Received 5 June 2021; Revised 8 August 2021; Accepted 14 August 2021; Published 21 September 2021

Academic Editor: Lawrence Aderemi Olatunji

Copyright © 2021 Guoqing Yao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Angiotensin-III (Ang-III) is the downstream product of angiotensin-II (Ang-II) metabolized by aminopeptidase A (APA). At present, the research of Ang-III mainly concentrates on hypertension and the central renin-angiotensin system (CAS). However, few studies have focused on the relationship between Ang-III and coronary atherosclerosis (CAS).

Methods and Results. Plasma Ang-III and APA levels were measured by the enzyme-linked immunosorbent assay (ELISA) in 44 normal subjects and 84 patients confirmed as having CAS by coronary angiography. Circulating Ang-III levels were significantly lower in patients with CAS than in normal controls (P = 0.013). APA levels were slightly lower in the CAS group (P = 0.324). According to the severity of atherosclerosis, CAS patients were divided into two groups. Compared with the controls, the APA and Ang-III levels were lower in the high scoring group and APA decreased significantly.

Conclusions. Circulating Ang-III levels were reduced in patients with CAS, and the possible reason may be related to the decrease in the APA level.

1. Introduction

As an important component of the renin-angiotensin system (RAS), angiotensin-II (Ang-II) has been considered to play a crucial role in the occurrence and development of coronary atherosclerosis (CAS) [1, 2]. This is based on the strong position of the classical axis of angiotensinogen/renin/angiotensin-converting enzyme (ACE)/Ang-II/Ang-II type 1 receptor (AT1R)/aldosterone in RAS. Derived from the metabolism of this classic axis, there are other axes including the Ang-I/Ang-II/aminopeptidase A (APA)/Ang-III/AT2R/-NO/cGMP axis and the Ang-I/Ang-II/ACE2/Ang-(1-7)/Mas receptor axis [3]. Hence, the peptides or enzymes in the these axes, such as Ang-III, Ang-(1-7), and ACE2, have aroused widespread concern [2, 4–6]. Ang-III is normally produced by the intrarenal metabolism of Ang-II by APA, which can be further processed into Ang-(3-8), namely, Ang-IV. After the biological activity of Ang-III was discovered, many studies thought that it had similar function with Ang-II [7]. Since Ang-III has a high clearance rate in peripheral circulation and its effects would be masked by Ang-II under normal physiological conditions [7, 8], little is known about the level and influence of Ang-III in the peripheral circulation of patients with CAS. This study was aimed at exploring the plasma level of Ang-III in patients with CAS. It is expected to further improve the research of RAS in coronary artery disease and provide new ideas for the treatment and prevention of coronary atherosclerosis.

2. Materials and Methods

2.1. Participants. A total of 84 patients with CAS confirmed by coronary angiography during hospitalization in the Department of Cardiology, Qilu Hospital of Shandong University, were prospectively collected. During the same period, 44 normal people were collected from the surgery department of our hospital as controls. The CAS group was required to meet the following conditions: (1) patients who needed coronary angiography due to new-onset angina attack or have a history of angina attack and (2) those that
had atherosclerosis confirmed by coronary angiography. Patients with any of the following were excluded: (1) having history of hypertension or newly discovered hypertension after admission (the systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg), (2) taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) within 1 month, (3) having moderate or severe anemia (hemoglobin < 90 g/l), and (4) having severe rheumatic, infectious, hematologic, or other systemic diseases. The controls from the surgery department met the following conditions: (1) all included subjects only suffered from diseases related to bone and joint degeneration, such as lumbar disc herniation. Subjects with any chronic disease were excluded. (2) Patients are not taking medicine within 1 month. This study was approved by the ethics committee of Qilu Hospital of Shandong University, and all patients provided written informed consent before participating.

2.2. Anthropometric Data and Blood Sampling. All samples of the two groups were collected prior to surgery or medication. All enrolled patients had a fasting blood sample drawn from the antecubital vein after fasting for 8 hours, and these samples were sent to the department of hospital laboratory for the detection of cardiac enzyme, blood glucose, lipid profile, serum creatinine, urea nitrogen, and other indicators. In addition, 5 ml of fresh blood was collected using an anticoagulant tube containing EDTA and centrifuged at 3000 rpm for 15 minutes at 4°C within one hour after collection. Plasma was collected in 1.5 ml EP tubes and stored at -80°C until analysis. Plasma Ang-III levels were determined using commercial enzyme-linked immunosorbent assay (ELISA) kits (BioVision, San Francisco, USA). Plasma APA levels were tested using ELISA kits from Abbexa (Cambridge, UK). All subjects received electrocardiogram and echocardiography examination. Anthropometric data such as gender, age, heart rate, smoking history, and blood pressure were obtained retrospectively from the hospital medical record query system.

2.3. Coronary Angiography. Coronary angiography is to insert a catheter through the femoral or radial artery of the thigh to the ascending aorta and then explore the left or right coronary ostia. Inject an iodine contrast agent to visualize the coronary arteries, which can clearly reveal the coronary artery anatomic deformity and the location, degree, or scope of the obstructive lesions. The coronary angiography results were evaluated by two specialists independently. Depending on the location, severity of the stenosis, and clinical symptoms, specialists may perform balloon dilatation or stenting depending on the situation through this procedure.

2.4. Statistical Analysis. All statistical analyses were performed by using SPSS 25.0. Data conforming to normal distribution were shown as mean values ± standard deviation (X ± S). Data that did not conform to the normal distribution were log-transformed. Differences among continuous variables between two groups were evaluated using two-sample t-tests. One-way analysis of variance (ANOVA) was used to compare the differences among the three groups. Categorical variables were expressed as frequencies (%) and tested by the chi-square test. A P value < 0.05 was considered statistically significant.

3. Results

3.1. Clinical and Biochemical Characteristics of the Study Population at Baseline. The demographic and biochemical characteristics of the subjects are summarized in Table 1. A total of 128 subjects, including 84 patients with CAS and 44 control subjects, were included in the study. There were no differences in gender, smoking history, heart rate, and age. For biochemical characteristics, there were no differences in serum potassium, Scr, BUN, blood glucose, and TG. The LDL-c, TC, and HDL-c were lower in patients with CAS compared with control subjects. For cardiac enzyme, the cTnI was higher in the CAS group than in controls. There was no difference in blood pressure between the two groups. All CAS subjects received coronary angiography. Forty-five patients received coronary stent implantation, six patients underwent drug coated balloon dilatation, and three patients needed coronary artery bypass grafting. The remaining 30 patients did not receive treatment during coronary angiography.

3.2. Plasma Levels of Ang-III and APA. Ang-III levels were significantly lower in patients with coronary atherosclerosis (5.6 ± 1.9 ng/ml) than in controls (6.5 ± 2.1 ng/ml) (P = 0.013) (Table 2). The APA levels were slightly lower in the CAS group (P = 0.324).

3.3. Correlation between Ang-III and the Severity of Atherosclerosis. To explore whether there is a relationship between the Ang-III level and severity of CAS, we used the Gensini score [9] to quantify the severity of CAS. Higher scores mean more severe CAS. We sorted the calculated scores and divided them into two groups in order (Table 3). The APA (1.38 ± 0.56 ng/ml) and Ang-III (4.25 ± 1.41 ng/ml) levels were lower in the high scoring group, and APA decreased significantly (P = 0.037). Ang-III levels displayed the same trend though it was not significant.

4. Discussion

Ang-III has been widely concerned since it was found to be a vasoactive peptide. Because it is generated by removing N-terminal single amino acid from Ang-II by aminopeptidase, the initial researchers first considered that its function is similar to that of Ang-II. Starting from this study point, researchers have successively found its role in sodium and water regulation, promotion of aldosterone release, blood pressure regulation, proinflammation, etc. [7, 10–14]. And most of its effects are thought to be mediated by AT1R. In central RAS, Ang-III is considered to be an essential substance acting on AT1R to exert a pressor effect, and its effect even exceeds that of Ang-II [6]. However, with the discovery of the Ang-II/APA/Ang-III/AT2R/NO/cGMP axis and the study of the role of AT2R activation in cardiovascular disease [3, 15, 16], it was found that Ang-III has positive effects
AT1R distribution, so its function has not been paid much
attention to. To explore whether there is a relationship
between endogenous circulating Ang-III and CAS, we exam-
ined the levels of Ang-III in the peripheral circulation. The
results showed that the levels of Ang-III in the CAS group
were significantly lower and the APA levels were slightly
lower than those in controls. To further explore whether
Ang-III level is associated with the severity of CAS, we used
the Gensini score to quantify the severity of CAS. We can see
that APA levels were significantly lower in the high scoring
group, and Ang-III levels displayed the same trend though
it was not significant. Regarding this result, we have several
hypotheses as follows. (1) In pathological conditions such
as myocardial infarction [19], it has been demonstrated that
AT2R expression is upregulated. In a myocardial ischemia-
reperfusion injury model [20], Ang-III combines with
AT2R to produce NO and cGMP, which are involved in the
early protection of myocardial ischemia. Ang-III, as an
important AT2R agonist, may be more likely to bind to
and act in the ischemic environment caused by coronary
atherosclerosis. Secondly, Ang-III can be metabolized into
Ang-IV by aminopeptidase N, and Ang-IV has also been
studied as having a myocardial protective effect [21]. The
consumption of Ang-III can be increased either by combin-
ing with AT2R directly or by metabolizing to Ang-IV. We
also speculate that Ang-III may increase in the early stage
of atherosclerosis in a compensatory manner. Since the
patients in our study were mostly in the late stage, this point
could be explored in future study. (2) We have known that
Ang-III is mainly derived from the metabolism of Ang-II
by APA and will be metabolized into Ang-IV by APN. In
the peripheral circulation of patients with essential hyper-
tension [22], APA activity is attenuated and APN activity
is enhanced, presumably leading to decreased Ang-III pro-
duction and increased metabolism. We get inspiration from
this research, so we measured the concentration of APA in
both groups. The results showed that the APA levels in the
CAS group were slightly lower than those in the control
group. Then, we divided the CAS group into two groups
according to their severity. The APA levels decreased signif-
ically in the severe group. Therefore, we speculated that the
decrease in Ang-III might be related to the decrease in APA.
And this shows a correlation between Ang-III and the sever-
cy of CAS. (3) In addition to the concentration changes due
to the upstream and downstream factors speculated above,
Ang-III may itself decrease expression under coronary ath-
 erosclerotic conditions.

Of course, there are also limitations in our study. Firstly,
due to funding constraints, we choose ELISA kits to detect
the samples. The overall levels of Ang-III were higher than
teoretical ones perhaps due to its high sensitivity. It is bet-
ter to choose liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) for accurate quantification [23].
Secondly, in this experiment, we did not focus much atten-
tion on Ang-II. Ang-II is considered to have proatherogenic
effects, and the plasma Ang-II levels have been confirmed to
be higher in patients with coronary atherosclerosis [2, 24].
So we did not assume that the decrease in Ang-III was due
to the decrease in Ang-II. But if we measured the concentra-
tion of rennin, angiotensinogen, and Ang-II, the results

\[
\begin{array}{|c|c|c|}
\hline
\text{Gender (female/male)} & \text{Controls (n = 44)} & \text{CAS (n = 84)} & P \text{ value} \\
\hline
\text{Age (years)} & 54 \pm 12 & 57 \pm 8 & 0.641 \\
\hline
\text{Smoking (\%)} & 34 & 45 & 0.995 \\
\hline
\text{Heart rate} & 75 \pm 6 & 73 \pm 11 & 0.191 \\
\hline
\text{TC (mmol/l)} & 4.6 \pm 1.2 & 3.7 \pm 1.1 & <0.001 \\
\hline
\text{LDL-c (mmol/l)} & 2.6 \pm 0.8 & 2.0 \pm 0.9 & <0.001 \\
\hline
\text{TG (mmol/l)} & 1.4 \pm 0.6 & 1.6 \pm 0.9 & 0.33 \\
\hline
\text{BUN (\mu mol/l)} & 70 \pm 14 & 74 \pm 14 & 0.087 \\
\hline
\text{HDL-c (mmol/l)} & 1.2 \pm 0.3 & 1.0 \pm 0.2 & 0.002 \\
\hline
\text{Scr (mmol/l)} & 122.9 \pm 8.6 & 122.0 \pm 9.6 & 0.601 \\
\hline
\text{Blood glucose} & 7.4 \pm 7.4 & 72.0 \pm 8.0 & 0.104 \\
\hline
\text{systolic blood pressure} & 5.2 \pm 0.7 & 5.5 \pm 1.5 & 0.268 \\
\hline
\text{Blood pressure} & 0 \pm 15.9 & 0.78 \pm 93.32 & <0.001 \\
\hline
\text{cTnI} & 1.33 \pm 1.0 & 1.7 \pm 2.4 & 0.316 \\
\hline
\text{CK-MB} & 80.1 \pm 48.6 & 72.8 \pm 54.2 & 0.612 \\
\hline
\text{Serum potassium} & 4.2 \pm 0.3 & 4.1 \pm 0.4 & 0.427 \\
\hline
\end{array}
\]

\text{CAS: coronary atherosclerosis; TC: total cholesterol; LDL-c: low-density lipoprotein cholesterol; TG: triglyceride; Scr: serum creatinine; BUN: blood urea nitrogen; HDL-c: high-density lipoprotein cholesterol; SBP: systolic blood pressure; DBP: diastolic blood pressure; cTnI: cardiac troponin I; CK: creatine kinase; CK-MB: creatine kinase isoenzyme.}

\[
\begin{array}{|c|c|c|}
\hline
\text{Ang-III (ng/ml)} & 6.5 \pm 2.1 & 5.6 \pm 1.9 & 0.013 \\
\hline
\text{APA (ng/ml)} & 1.92 \pm 1.15 & 1.74 \pm 0.90 & 0.324 \\
\hline
\end{array}
\]

\[
\begin{array}{|c|c|c|c|}
\hline
\text{Ang-III (ng/ml)} & 5.16 \pm 2.07 & 4.25 \pm 1.41 & 6.5 \pm 2.1 & 0.11 \\
\hline
\text{APA (ng/ml)} & 1.98 \pm 1.12 & 1.38 \pm 0.56 & 1.92 \pm 1.15 & 0.037 \\
\hline
\end{array}
\]
would be more convincing. Thirdly, the sample size was relatively small and the enrolled patients were mostly in the late stage of atherosclerosis, which leads to limitations of more analysis. We aim to recruit more subjects and enlarge the sample size.

In conclusion, our present study found that the Ang-III levels were decreased in patients with CAS for the first time, which might be related to the decrease in APA. This requires a larger sample size and more precise testing methods for confirmation.

Data Availability

All data generated or analysed during this study are included in this published article. The data have been deposited in Figshare: (DOI:10.6084/m9.figshare.15657402). Requests for material should be made to the corresponding authors.

Conflicts of Interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Acknowledgments

This work was supported by the grants of the National Natural Science Foundation of China (Nos. 81920108003 and 81770442), the grants of the International Cooperation Program of National Natural Science Foundation of China (No. 8192010800), and the grants of the Shandong Natural Science Foundation (No. ZR2017QH009, Li Wenjing) and Taishan Scholar Project of Shandong Province of China (Zhang C).

References

[1] K. M. Colafella, D. M. Bovée, and A. J. Danser, “The renin-angiotensin-aldosterone system and its therapeutic targets,” Experimental Eye Research, vol. 186, p. 107680, 2019.

[2] G. M. Silva, M. S. França-Falcão, N. T. M. Calzerra et al., “Role of renin-angiotensin system components in atherosclerosis: focus on Ang-II, ACE2, and Ang-1–7,” Frontiers in Physiology, vol. 11, p. 1067, 2020.

[3] X. C. Li, J. Zhang, and J. L. Zhuo, “The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases,” Pharmacological research, vol. 125, no. Part A, pp. 21–38, 2017.

[4] M. P. Ocaranza, L. Michea, M. Chiong, C. F. Lagos, S. Lavadero, and J. E. Jallil, “Recent insights and therapeutic perspectives of angiotensin-(1–9) in the cardiovascular system,” Clinical Science (London, England), vol. 127, no. 9, pp. 549–557, 2014.

[5] S. e Silva AC, K. D. Silveira, A. J. Ferreira, and M. M. Teixeira, “ACE2, angiotensin-(1–7) and Mas receptor axis in inflammation and fibrosis,” British Journal of Pharmacology, vol. 169, no. 3, pp. 477–492, 2013.

[6] V. G. Yugandhar and M. A. Clark, “Angiotensin III: a physiological relevant peptide of the renin angiotensin system,” Peptides, vol. 46, pp. 26–32, 2013.

[7] I. Gammelgaard, S. Wamberg, and P. Bie, “Systemic effects of angiotensin III in conscious dogs during acute double blockade of the renin-angiotensin-aldosterone-system,” Acta Physiologica (Oxford, England), vol. 188, no. 2, pp. 129–138, 2006.

[8] C. Wamberg, R. R. Ploving, N. C. Sandgaard, and P. Bie, “Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs,” American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, vol. 285, no. 5, pp. R971–R980, 2003.

[9] G. P. Rampidis, G. Benetos, D. C. Benz, A. A. Giannopoulos, and R. R. Buechel, “A guide for Genisini score calculation,” Atherosclerosis, vol. 287, pp. 181–183, 2019.

[10] H. W. Kim, Y. O. Kim, S. A. Yoon, J. S. Han, H. B. Chun, and Y. S. Kim, “Angiotensin III increases monocyte chemoattractant protein-1 expression in cultured human proximal tubular epithelial cells,” The Korean Journal of Internal Medicine, vol. 31, no. 1, pp. 116–124, 2016.

[11] A. Z. Alanazi and M. A. Clark, “Effects of angiotensin III on c-Jun N terminal kinase in Wistar and hypertensive rat vascular smooth muscle cells,” Peptides, vol. 123, p. 170204, 2020.

[12] B. A. Kemp, N. L. Howell, S. R. Keller et al., “Defective renal angiotensin III and AT2 receptor signaling in prehypertensive spontaneously hypertensive rats,” Journal of the American Heart Association, vol. 8, no. 9, article e012016, 2019.

[13] J. L. Zhuo and X. C. Li, “Angiotensin III/AT2 receptor/NHE3 signaling pathway in the proximal tubules of the kidney: a novel natriuretic and antihypertensive mechanism in hypertension,” Journal of the American Heart Association, vol. 8, no. 9, article e012644, 2019.

[14] J. Yatabe, M. Yoneda, M. S. Yatabe et al., “Angiotensin III stimulates aldosterone secretion from adrenal gland partially via angiotensin II type 2 receptor but not angiotensin II type 1 receptor,” Endocrinology, vol. 152, no. 4, pp. 1582–1588, 2011.

[15] E. Kaschina, P. Namsolleck, and T. Unger, “AT2 receptors in cardiovascular and renal diseases,” Pharmacological research, vol. 125, no. Part A, pp. 39–47, 2017.

[16] R. M. Carey, “Update on angiotensin AT2 receptors,” Current Opinion in Nephrology and Hypertension, vol. 26, no. 2, pp. 91–96, 2017.

[17] S. H. Padia, N. L. Howell, H. M. Siragy, and R. M. Carey, “Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat,” Hypertension, vol. 47, no. 3, pp. 537–544, 2006.

[18] S. H. Padia, B. A. Kemp, N. L. Howell, M. C. Fournie-Zaluski, B. P. Roques, and R. M. Carey, “Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats,” Hypertension, vol. 51, no. 2, pp. 460–465, 2008.

[19] Y. Nio, H. Matsubara, S. Murasawa, M. Kanasaki, and M. Inada, “Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction,” The Journal of Clinical Investigation, vol. 95, no. 1, pp. 46–54, 1995.

[20] B. M. Park, S. Gao, S. A. Cha, B. H. Park, and S. H. Kim, “Cardioprotective effects of angiotensin III against ischemic injury via the AT2 receptor and KATP channels,” Physiological Reports, vol. 1, no. 6, article e00151, 2013.

[21] J. K. Ho and D. A. Nation, “Cognitive benefits of angiotensin IV and angiotensin-(1–7): a systematic review of experimental studies,” Neuroscience and Biobehavioral Reviews, vol. 92, pp. 209–225, 2018.
[22] R. Sanchez-Agesta Ortega, M. J. Arias de Saavedra-Alías, B. Sánchez-Muñoz, M. J. Martínez-Martos, and J. M. Ramírez-Expósito, "Circulating aminopeptidase activities in men and women with essential hypertension," *Current Medicinal Chemistry*, vol. 20, no. 38, pp. 4935–4945, 2013.

[23] F. Chen, Z. Cheng, Y. Peng et al., "A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay for simultaneous quantification of aldosterone, renin activity, and angiotensin II in human plasma," *Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences*, vol. 1179, p. 122740, 2021.

[24] W. Li, J. Li, P. Hao et al., "Imbalance between angiotensin II and angiotensin-(1-7) in human coronary atherosclerosis," *Journal of the Renin-Angiotensin-Aldosterone System*, vol. 17, no. 3, p. 147032031665961, 2016.